Expression of Epstein‐Barr virus nuclear antigen‐2 (EBNA2) induces CD21/CR2 on B and T cell lines and shedding of soluble CD21
暂无分享,去创建一个
[1] F. Fend,et al. Role of Epstein‐Barr virus and soluble CD21 in persistent polyclonal B‐cell lymphocytosis , 1995, British journal of haematology.
[2] E. Kremmer,et al. B‐cell proliferation and induction of early G1‐regulating proteins by Epstein‐Barr virus mutants conditional for EBNA2. , 1995, The EMBO journal.
[3] D. Fearon,et al. Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes , 1993, The Journal of experimental medicine.
[4] A. Goetz,et al. Complete local tumor remission after therapy with extra‐corporeally applied high‐energy shock waves (HESW) , 1993, International journal of cancer.
[5] W. Prodinger,et al. Determination of soluble CD21 as a parameter of B cell activation , 1993, Clinical and experimental immunology.
[6] V. Vetvicka,et al. Complement factors H and I synthesized by B cell lines function to generate a growth factor activity from C3. , 1993, Journal of immunology.
[7] M. Holder,et al. A subset of anti‐CD21 antibodies promote the rescue of germinal center B cells from apoptosis , 1993, European journal of immunology.
[8] G. Lenoir,et al. Epstein‐barr virus (EBV) nuclear‐antigen‐2‐induced up‐regulation of cd21 and cd23 molecules is dependent on a permissive cellular context , 1993, International journal of cancer.
[9] E. Lundgren,et al. Transient expression of the Epstein-Barr virus LMP1 gene in B-cell chronic lymphocytic leukemia cells, T cells, and hematopoietic cell lines: cell-type-independent-induction of CD23, CD21, and ICAM-1. , 1993, Leukemia.
[10] J. Bonnefoy,et al. CD21 is a ligand for CD23 and regulates IgE production , 1992, Nature.
[11] M. Kazatchkine,et al. Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL. , 1992, Journal of immunology.
[12] N. Ling,et al. Properties of soluble CR2 in human serum. , 1992, Immunobiology.
[13] D. Fearon,et al. Suppression of the immune response by a soluble complement receptor of B lymphocytes. , 1991, Science.
[14] I. Maclennan,et al. Recombinant 25‐kDa CD23 and interleukin 1α promote the survival of germinal center B cells: evidence for bifurcation in the development of centrocytes rescued from apoptosis , 1991, European journal of immunology.
[15] N. Ling,et al. Cellular origins of serum complement receptor type 2 in normal individuals and in hypogammaglobulinaemia , 1991, Clinical and experimental immunology.
[16] J. Chen,et al. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinicopathologic and molecular analysis. , 1991, Blood.
[17] M. Kazatchkine,et al. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. , 1991, Journal of immunology.
[18] B. Myones,et al. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. , 1990, The Journal of biological chemistry.
[19] J. Banchereau,et al. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23 , 1990, Journal of virology.
[20] G. Sauvageau,et al. Epstein-Barr virus receptor expression on human CD8+ (cytotoxic/suppressor) T lymphocytes. , 1990, The Journal of general virology.
[21] W. Hammerschmidt,et al. Genetic analysis of immortalizing functions of EpsteinBarr virus in human B lymphocytes , 1989, Nature.
[22] J. Harley,et al. Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor. , 1989, The Journal of biological chemistry.
[23] D. Fearon,et al. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). , 1989, Advances in immunology.
[24] E. Kieff,et al. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity , 1988, Journal of virology.
[25] John D Lambris,et al. Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies , 1988, European journal of immunology.
[26] I. Kobayashi,et al. Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease , 1988, Nature.
[27] J. Fingeroth,et al. Characterization of a T-lymphocyte Epstein-Barr virus/C3d receptor (CD21) , 1988, Journal of virology.
[28] G. Guy,et al. Soluble CD23 is released by B lymphocytes cycling in response to interleukin 4 and anti‐Bp50 (CDw40) , 1988, European journal of immunology.
[29] R. Lier,et al. Signals involved in T cell activation. T cell proliferation induced through the synergistic action of anti‐CD28 and anti‐CD2 monoclonal antibodies , 1988, European journal of immunology.
[30] T. Schulz,et al. Identification and characterization of a novel membrane activation antigen with wide cellular distribution , 1988, European journal of immunology.
[31] T. Schulz,et al. Structural and functional analysis of CR2/EBV receptor by means of monoclonal antibodies and limited tryptic digestion. , 1988, Immunology.
[32] E. Kieff,et al. Epstein-barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis , 1987, Cell.
[33] L. Hutt-Fletcher. Synergistic activation of cells by Epstein-Barr virus and B-cell growth factor , 1987, Journal of virology.
[34] J. Thompson,et al. Selective radiolabeling of cell surface proteins to a high specific activity. , 1987, Biochemistry.
[35] B. Myones,et al. Identification of a spontaneously shed fragment of B cell complement receptor type two (CR2) containing the C3d-binding site. , 1987, Complement.
[36] M. Epstein,et al. The Epstein-Barr virus : recent advances , 1986 .
[37] M. Rowe,et al. Ligation of the CD23, p45 (BLAST‐2, EBVCS) antigen triggers the cell‐cycle progression of activated B lymphocytes , 1986, European journal of immunology.
[38] G. Nemerow,et al. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes. , 1985, Journal of immunology.
[39] J. Platt,et al. Monoclonal antibodies to the 140,000 mol wt glycoprotein of B lymphocyte membranes (CR2 receptor) initiates proliferation of B cells in vitro. , 1985, Blood.
[40] T. Schulz,et al. Growth control of activated, synchronized murine B cells by the C3d fragment of human complement , 1985, Nature.
[41] R. Frade,et al. Enhancement of human B cell proliferation by an antibody to the C3d receptor, the gp 140 molecule , 1985, European journal of immunology.